Oncimmune Holdings plc has placed and converted debt into equity
Oncimmune Holdings plc has raised US$2.9 million (£2.3 million) by placing and converting debt into equity to advance its pioneering work in autoantibody profiling and biomarker discovery, along with an additional US$4.1 million (€4 million) from debt conversion.
Oncimmune Holdings plc develops and commercializes technologies for cancer diagnosis in the UK, North America, Europe and beyond. The company offers EarlyCDT-Lung, a blood test for the early detection of lung cancer. Additionally, Oncimmune develops SeroTag, a platform for discovering and validating biomarkers to help stratify patients across multiple cancer indications, infectious diseases and autoimmune conditions. The company also offers NavigAID disease-specific stratification panels. Founded in 2015, Oncimmune is based in Nottingham, UK.
Oaklins Cavendish, one of Oaklins’ member firms in the UK, advised Oncimmune Holdings plc on this transaction.
Contacter l'équipe de la transaction
Transactions connexes
Darien S.p.A. has launched a voluntary public tender offer for NVP S.p.A.
Darien S.p.A. has initiated a voluntary public tender offer for NVP S.p.A.
En apprendre plusGenerali has expanded its footprint in Bulgaria by acquiring one of the top health insurers on the market
Doverie United Holding has successfully completed the sale of United Health Insurance Fund Doverie (Doverie) to Generali CEE Holding.
En apprendre plusCustomerXPs Software (Clari5) has been acquired by Perfios Software Solutions
Bengaluru-based SaaS firm Perfios Software Solutions Private Ltd. has acquired 100% of the equity shares in the fraud-detection platform CustomerXPs Software Private Ltd. (Clari5) for an undisclosed amount, enhancing its anti-financial crime management suite for financial institutions.
En apprendre plus